[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100568178":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":11,"centralContacts":23,"locations":30,"responsibleParty":45,"collaborators":11,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":11,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":11,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":11,"overallStatus":32,"whyStopped":11,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"National Taiwan University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"GKB7","EXPERIMENTAL",null,[13],"Other: probiotic (GKB7\u002Fplacebo)",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo","PLACEBO_COMPARATOR",[13],[19],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"probiotic (GKB7\u002Fplacebo)","The objectives of this double-blind randomized placebo-controlled trial are to evaluate the tolerability, safety, and efficacy of the probiotic intervention with Clostridium butyricum GKB7 among 90 4-15-year-old children and adolescents with a clinical diagnosis of ASD according to the DSM-5",[9,15],[24],{"name":25,"role":26,"phone":27,"phoneExt":28,"email":29},"Susan Shur-Fen Gau, MD, PhD","CONTACT","+886-2-23123456","266802","gaushufe@ntu.edu.tw",[31],{"facility":5,"status":32,"city":33,"state":11,"zip":11,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"RECRUITING","Taipei","Taiwan","TW",{"type":37,"coordinates":38},"Point",[39,40],121.52639,25.05306,{"lat":40,"lon":39},[43],{"name":25,"role":26,"phone":44,"phoneExt":28,"email":29},"+ 886-2-23123456",{"type":46,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100568178","exploring-the-gut-brain-behavior-axis-with-biomarkers-probiotic-efficacy-and-artificial-intelligence-algorithms-100568178",false,"NCT06677840","Exploring the Gut-Brain-Behavior Axis With Biomarkers, Probiotic Efficacy, and Artificial Intelligence Algorithms","Precision Health in Autism: Exploring the Gut-Brain-Behavior Axis With Biomarkers, Probiotic Efficacy, and Artificial Intelligence Algorithms","Inclusion Criteria:\n\n* Children and adolescents aged 4 to 15 who are clinically diagnosed with ASD according to DSM-5 criteria and confirmed by the ADI-R\u002FADOS.\n* Caregivers cooperate with all the assessments and stool and blood collection.\n\nExclusion Criteria:\n\n* A history of major psychiatric disorders (e.g., schizophrenia, bipolar disorder, major depression), neurological disorders, and substances use disorders.\n* Difficulty following instructions.\n* Consumption of antibiotics and yogurt or probiotic products two weeks prior to enrollment.","ALL","4 Years","15 Years",{"count":58,"type":59},110,"ESTIMATED","INTERVENTIONAL",[62],"NA","This groundbreaking human study on the ASD microbiome includes probiotic clinical trials, investigation of treatment biomarkers, machine learning\u002Fdeep learning platform development for ASD classification and prediction, and identification of diagnostic biomarkers. Upon completion, the investigators anticipate publishing at least 12 SCI papers and\u002For patents and establishing an auxiliary diagnosis platform for both clinical and academic purposes. The findings will offer new insights into the pathogenetic mechanisms, improving early detection, diagnosis, and treatment, ultimately advancing precision medicine for ASD.",[65],"Autism Spectrum Disorder","2026-06-16",{"date":68,"type":69},"2026-06-18","ACTUAL",{"date":71,"type":69},"2024-05-01",{"date":73,"type":59},"2028-04-30",{"name":5,"class":6},1]